Enzymatic DNA for production of AAV adenoassociated virus

TAAV Biomanufacturing Solutions, S.L.U (TAAV), a subsidiary of Asklepios Biopharmaceuticals (AskBio) and Bayer AG.
TAAV manufactures and offers to the international market neDNA™: enzymatic DNA used for adeno-associated virus (AAV) gene therapies.
neDNA™, the enzymatic DNA manufactured by TAAV is an alternative to plasmid DNA commonly used in AAV manufacturing whose main advantage is higher yields of DNA material: it significantly shortens manufacturing times and facilitates faster production of AAVs with a higher safety profile by eliminating residual bacterial plasmid DNA sequences.
TAAV was founded in 2019 and became wholly owned by AskBio in 2022. The company’s headquarters, as well as production facility and laboratories, are located in San Sebastian, Spain.
The company offers this innovative enzymatic DNA solution to the biopharmaceutical and gene therapy industry. Gene therapy is applied to congenital diseases that affect a single gene and consists of replacing the altered gene, which is not working properly or is missing in the person’s DNA and is not fulfilling its function. This requires a vehicle capable of transporting the correct gene to the cells within the body. Adeno-associated viruses (AAVs) have shown great potential in this area by optically carrying the gene of interest with the advantage that they do not reproduce in the body and do not cause associated infections.

CEO
Dolores Baksh

COO
Alfredo Martínez

WEB
TAAV Biomanufacturing Solutions

DIVESTED COMPANY
2018-2019 (Acquired by Asklepios Biopharmaceuticals (AskBio) y Bayer AG)